Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer

被引:0
|
作者
Shen, Qiang [1 ]
Murakami, Kiichi [1 ]
Sotov, Valentin [1 ]
Butler, Marcus [1 ,2 ,3 ]
Ohashi, Pamela S. [1 ,4 ,5 ]
Reedijk, Michael [1 ,5 ,6 ]
机构
[1] Univ Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada
[4] Univ Toronto, Dept Immunol, Med Sci Bldg,1 Kings Coll Circle,Room 7205, Toronto, ON M5S 1A8, Canada
[5] Univ Toronto, MaRS Ctr, Dept Med Biophys, Toronto Med Discovery Tower,101 Coll St,Room 15-70, Toronto, ON M5G 2M9, Canada
[6] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, 610 Univ Ave,Suite 8-411, Toronto, ON M5G 2M9, Canada
来源
SCIENCE ADVANCES | 2024年 / 10卷 / 44期
基金
加拿大健康研究院;
关键词
TUMOR-ASSOCIATED MACROPHAGES; SIGNALING PATHWAY; CELLS; INFLAMMATION; NIVOLUMAB; THERAPY; INVASIVENESS; EXPRESSION; MICROENVIRONMENT; PEMBROLIZUMAB;
D O I
10.1126/sciadv.ado8275
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Aberrant Notch, which is a defining feature of triple-negative breast cancer (TNBC) cells, regulates intercellular communication in the tumor immune microenvironment (TIME). This includes tumor-associated macrophage (TAM) recruitment through Notch-dependent cytokine secretion, contributing to an immunosuppressive TIME. Despite the low response rate of TNBC to immune checkpoint blockade (ICB), here, we report that inhibition of Notch-driven cytokine-mediated programs reduces TAMs and induces responsiveness to sequentially delivered ICB. This is characterized by the emergence of GrB+ cytotoxic T lymphocytes (CTLs) in the primary tumor. A more impressive effect of sequential treatment is observed in the lung where TAM depletion and increased CTLs are accompanied by near-complete abolition of metastases. This is due to (i) therapeutic reduction in Notch-dependent, prometastatic circulating factors released by the primary tumor, and (ii) elevated PD ligand 1 (PD-L1) in lung metastases, rendering them profoundly sensitive to ICB. These findings highlight the potential of combination cytokine inhibition and ICB as an immunotherapeutic strategy in TNBC.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Inhibiting glycolysis facilitated checkpoint blockade therapy for triple-negative breast cancer
    Chong Li
    Yu Tang
    Ruizhi Zhang
    Liang Shi
    Jianying Chen
    Peng Zhang
    Ning Zhang
    Wei Li
    Discover Oncology, 16 (1)
  • [22] SCD-1 blockade sensitizes triple negative breast cancer to immune checkpoint inhibition.
    Vivekanandhan, Sneha
    Trynda, Justyna
    Marlow, Laura A.
    Shreeder, Barath
    Miller, James L.
    Kase, Adam M.
    Tan, Winston
    Knutson, Keith L.
    Copland, John A.
    CANCER RESEARCH, 2021, 81 (13)
  • [23] Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer
    Papakyriacou, Irineos
    Kutkaite, Ginte
    Bedos, Marta Rubies
    Nagarajan, Divya
    Alford, Liam P.
    Menden, Michael P.
    Mao, Yumeng
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [24] Factors associated with response to neoadjuvant chemotherapy and immune checkpoint inhibition in triple-negative breast cancer.
    Levee, Alexis
    Wong, Megan
    Flores, Sarah
    Ruel, Nora H.
    Lavasani, Sayeh Moazami
    Patel, Niki
    Sedrak, Mina S.
    Stewart, Daphne B.
    Waisman, James Ross
    Yuan, Yuan
    Mortimer, Joanne E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] The Evolving Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Steiner, Meghan
    Tan, Antoinette R.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (05) : 305 - 315
  • [26] Our experience with immune checkpoint inhibitors in triple-negative breast cancer patients
    Nishio, Minako
    Kojitani, Yoshiki
    Kitashiro, Saya
    Ishiduka, Yasunobu
    Otsuka, Tomoyuki
    Nishida, Naohiro
    Fujisawa, Fumie
    Sugimoto, Naotoshi
    Yagi, Toshinari
    Souma, Ai
    Kanaoka, Haruka
    Oyamayama, Yuri
    Taniguchi, Azusa
    Nakajima, Satomi
    Seto, Yukiko
    Kusama, Hiroki
    Watanabe, Noriyuki
    Matsui, Saki
    Nakayama, Takahiro
    Kudou, Toshihiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1465 - S1465
  • [27] Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer
    Quintana, A.
    Saini, K. S.
    Vidal, L.
    Peg, V.
    Slebe, F.
    Loibl, S.
    Curigliano, G.
    Schmid, P.
    Cortes, J.
    ESMO OPEN, 2024, 9 (10)
  • [28] The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
    Singh, Sima
    Numan, Arshid
    Maddiboyina, Balaji
    Arora, Saahil
    Riadi, Yassine
    Md, Shadab
    Alhakamy, Nabil A.
    Kesharwani, Prashant
    DRUG DISCOVERY TODAY, 2021, 26 (07) : 1721 - 1727
  • [29] Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way
    Telli, M. L.
    Vinayak, S.
    ANNALS OF ONCOLOGY, 2019, 30 (03) : 347 - 348
  • [30] Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer
    Ren, Xijiao
    Cheng, Zhuo
    He, Jinming
    Yao, Xuemei
    Liu, Yingqi
    Cai, Kaiyong
    Li, Menghuan
    Hu, Yan
    Luo, Zhong
    NATURE COMMUNICATIONS, 2023, 14 (01)